The modified FACS calcein AM retention assay: A high throughput flow cytometer based method to measure cytotoxicity

Journal of Immunological Methods

Volumn 434, Issue , 2016, Pages 16-23

  Gillissen, M A ^a   Yasuda, E ^a   de Jong, G ^a   Levie, S E ^a   Go, D ^a   Spits, H ^a   van Helden, P M ^a   Hazenberg, M D ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

ADCC; Cancer; CDC; Cellular cytotoxicity; Monoclonal antibodies

Indexed keywords

RITUXIMAB; TRASTUZUMAB; CALCEIN AM; FLUORESCEIN DERIVATIVE; FLUORESCENT DYE;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CALCEIN-AM ASSAY; CELL LABELING; CELL SUSPENSION; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; CYTOTOXICITY; EC50; EFFECTOR CELL; FLOW CYTOMETER; FLUORESCENCE ACTIVATED CELL SORTING; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; BIOASSAY; CELL SURVIVAL; CHEMISTRY; FLOW CYTOMETRY; IMMUNOLOGY; NATURAL KILLER CELL; PROCEDURES; TUMOR CELL CULTURE; TUMOR CELL LINE;

BIOLOGICAL ASSAY; CELL LINE, TUMOR; CELL SURVIVAL; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; FLUORESCEINS; FLUORESCENT DYES; HUMANS; KILLER CELLS, NATURAL; RITUXIMAB; TRASTUZUMAB; TUMOR CELLS, CULTURED;

EID: 84964260958     PISSN: 00221759     EISSN: 18727905     Source Type: Journal    
DOI: 10.1016/j.jim.2016.04.002     Document Type: Article

References (21)

1. Bornstein G.G., et al. Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. Investig. New Drugs 2009, 28:561-574.
2. Boyle W. An extension of the 51Cr-release assay for the estimation of mouse cytotoxins. Transplantation 1968, 1-4.
3. Breton C.S. A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies. J. Hematol. Oncol. 2014, 1-13.
4. Cheng Z.J., et al. Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies. J. Immunol. Methods 2014, 414:69-81.
5. Chung S., et al. Characterization of in vitro antibody-dependent cell-mediated cytotoxicity activity of therapeutic antibodies - impact of effector cells. J. Immunol. Methods 2014, 407:63-75.
6. Galluzzi L., et al. Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ. 2009, 16:1093-1107.
7. Hatjiharissi E., et al. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc RIIIa-158 V/V and V/F polymorphism. Blood 2007, 110:2561-2564.
8. Heider K.H., et al. A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies. Blood 2011, 118:4159-4168.
9. Horsten von H.H., et al. Production of non-fucosylated antibodies by co-expression of heterologous GDP-6-deoxy-d-lyxo-4-hexulose reductase. Glycobiology 2010, 20:1607-1618.
10. Koene H.R., et al. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 1997, 90:1109-1114.
11. Le Garff-Tavernier M., et al. Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies. Leukemia 2010, 25:101-109.
12. McLellan J.S., et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 2013, 340:1113-1117.
13. Murray D.A. Development and validation of a Herceptin® neutralising antibody assay utilising the Promega ADCC reporter bioassay. Poster 2014, British society of immunology.
14. Naranbhai V., et al. Impact of blood processing variations on natural killer cell frequency, activation, chemokine receptor expression and function. J. Immunol. Methods 2011, 366:28-35.
15. Neri S., Mariani E., Meneghetti A., Cattini L., Facchini A. Calcein-acetyoxymethyl cytotoxicity assay: standardization of a method allowing additional analyses on recovered effector cells and supernatants. Clin. Vaccine Immunol. 2001, 8:1131-1135.
16. Parekh B.S., et al. Development and validation of an antibody-dependent cell-mediated cytotoxicity-reporter gene assay. mAbs 2014, 4:310-318.
17. Prang N., et al. Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines. Br. J. Cancer 2005, 342-348.
18. Tajeddine N., et al. Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death. Oncogene 2008, 27:4221-4232.
19. Thorn R.M., Palmer J.C., Manson L.A. A simplified 51Cr-release assay for killer cells. J. Immunol. Methods 1974, 4:301-315.
20. Wagner K., et al. Bispecific antibody generated with sortase and click chemistry has broad antiinfluenza virus activity. Proc. Natl. Acad. Sci. 2014, 111:16820-16825.
21. Winiarska M., et al. Statins impair antitumor effects of rituximab by inducing conformational changes of CD20. PLoS Med. 2008, 5.